Yuhui Huang

List of Publications by Year
in descending order

42 papers	6,535 citations	109321 35 h-index	265206 42 g-index
42 all docs	42 docs citations	42 times ranked	10430 citing authors

#	Article	IF	Citations
1	DLL1 orchestrates CD8⁺T cells to induce long-term vascular normalization and tumor regression. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	32
2	High stearic acid diet modulates gut microbiota and aggravates acute graft-versus-host disease. Signal Transduction and Targeted Therapy, 2021, 6, 277.	17.1	11
3	CTLA4 blockade promotes vessel normalization in breast tumors <i>via</i> the accumulation of eosinophils. International Journal of Cancer, 2020, 146, 1730-1740.	5.1	51
4	Tumor Vasculatures: A New Target for Cancer Immunotherapy. Trends in Pharmacological Sciences, 2019, 40, 613-623.	8.7	79
5	NCRâˆ’ group 3 innate lymphoid cells orchestrate IL-23/IL-17 axis to promote hepatocellular carcinoma development. EBioMedicine, 2019, 41, 333-344.	6.1	56
6	The Reciprocity between Radiotherapy and Cancer Immunotherapy. Clinical Cancer Research, 2019, 25, 1709-1717.	7.0	95
7	Improving immuneâ€“vascular crosstalk for cancer immunotherapy. Nature Reviews Immunology, 2018, 18, 195-203.	22.7	340
8	Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Science Translational Medicine, 2018, 10, .	12.4	153
9	Lentinan inhibits tumor angiogenesis via interferon Î³ and in a T cell independent manner. Journal of Experimental and Clinical Cancer Research, 2018, 37, 260.	8.6	40
10	Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. Journal of Clinical Investigation, 2018, 128, 2104-2115.	8.2	152
11	Targeting CXCR4-dependent immunosuppressive Ly6C ^{low} monocytes improves antiangiogenic therapy in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10455-10460.	7.1	97
12	Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential. International Journal of Nanomedicine, 2017, Volume 12, 1969-1983.	6.7	65
13	Myeloid-derived suppressor cell and macrophage exert distinct angiogenic and immunosuppressive effects in breast cancer. Oncotarget, 2017, 8, 54173-54186.	1.8	34
14	Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4470-4475.	7.1	251
15	Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. Science Translational Medicine, 2016, 8, 360ra135.	12.4	184
16	Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. Cancer Discovery, 2016, 6, 852-869.	9.4	318
17	Suppression of Hepatic Inflammation <i>via</i> Systemic siRNA Delivery by Membrane-Disruptive and Endosomolytic Helical Polypeptide Hybrid Nanoparticles. ACS Nano, 2016, 10, 1859-1870.	14.6	107
18	CXCR4 inhibition in tumor microenvironment facilitates antiâ€programmed death receptorâ€1 immunotherapy in sorafenibâ€treated hepatocellular carcinoma in mice. Hepatology, 2015, 61, 1591-1602.	7.3	355

#	Article	IF	Citations
19	Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 193-201.	7.4	11
20	Quantum dot/antibody conjugates for in vivo cytometric imaging in mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1350-1355.	7.1	109
21	Blockade of MMP14 Activity in Murine Breast Carcinomas: Implications for Macrophages, Vessels, and Radiotherapy. Journal of the National Cancer Institute, 2015, 107, .	6.3	106
22	Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles. ACS Nano, 2015, 9, 8689-8696.	14.6	134
23	Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology, 2014, 59, 1435-1447.	7.3	178
24	Benefits of Vascular Normalization Are Dose and Time Dependentâ€"Letter. Cancer Research, 2013, 73, 7144-7146.	0.9	89
25	Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma. Cell, 2013, 152, 1065-1076.	28.9	209
26	Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro-Oncology, 2013, 15, 1079-1087.	1.2	205
27	Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression. Journal of the National Cancer Institute, 2013, 105, 1188-1201.	6.3	101
28	Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy. Cancer Research, 2013, 73, 2943-2948.	0.9	535
29	Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17561-17566.	7.1	800
30	Combined targeting of HER2 and VEGFR2 for effective treatment of<i>HER2</i>-amplified breast cancer brain metastases. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3119-27.	7.1	131
31	Impaired lymphatic contraction associated with immunosuppression. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18784-18789.	7.1	246
32	C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 302-307.	7.1	85
33	Combinational Therapy of Interferon-Î± and Chemotherapy Normalizes Tumor Vasculature by Regulating Pericytes Including the Novel Marker RGS5 in Melanoma. Journal of Immunotherapy, 2011, 34, 320-326.	2.4	22
34	Polarization of Tumor-Associated Macrophages: A Novel Strategy for Vascular Normalization and Antitumor Immunity. Cancer Cell, 2011, 19, 1-2.	16.8	91
35	PDGF-D Improves Drug Delivery and Efficacy via Vascular Normalization, But Promotes Lymphatic Metastasis by Activating CXCR4 in Breast Cancer. Clinical Cancer Research, 2011, 17, 3638-3648.	7.0	67
36	Resuscitating Cancer Immunosurveillance: Selective Stimulation of DLL1-Notch Signaling in T cells Rescues T-cell Function and Inhibits Tumor Growth. Cancer Research, 2011, 71, 6122-6131.	0.9	64

#	Article	IF	Citations
37	Anti-Vascular Endothelial Growth Factor Treatment in Combination with Chemotherapy Delays Hematopoietic Recovery Due to Decreased Proliferation of Bone Marrow Hematopoietic Progenitor Cells. Journal of Thoracic Oncology, 2010, 5, 1410-1415.	1.1	17
38	Recruitment of Myeloid but not Endothelial Precursor Cells Facilitates Tumor Regrowth after Local Irradiation. Cancer Research, 2010, 70, 5679-5685.	0.9	253
39	Adenosine receptors in regulation of dendritic cell differentiation and function. Blood, 2008, 112, 1822-1831.	1.4	357
40	Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood, 2007, 110, 624-631.	1.4	198
41	Host and Direct Antitumor Effects and Profound Reduction in Tumor Metastasis with Selective EP4 Receptor Antagonism. Cancer Research, 2006, 66, 9665-9672.	0.9	99
42	Expression And Secretion Of Functional Recombinant 1 Scu-Pa:Av In Insect Cell Using Signal Peptides. Protein and Peptide Letters, 2004, 11, 49-55.	0.9	8